- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Emeryville Today
By the People, for the People
BioAge Labs Oral NLRP3 Inhibitor Shows Promise in Cardiovascular Trial
Biotech firm's lead drug candidate demonstrates strong safety and efficacy results, positioning it for potential proof-of-concept in 2026
Apr. 15, 2026 at 8:20pm
Got story updates? Submit your updates here. ›
BioAge's promising NLRP3 inhibitor drug could offer a new way to address the underlying inflammation driving cardiovascular disease.Emeryville TodayBioAge Labs, a biotech company based in Emeryville, California, has reported positive results from a Phase 1 trial of its oral NLRP3 inhibitor drug candidate BGE-102. The trial showed the drug was able to reduce high-sensitivity C-reactive protein (hsCRP) levels by 86% with a solid safety profile, potentially positioning it for proof-of-concept in cardiovascular disease this year.
Why it matters
NLRP3 inhibitors are a promising new class of drugs that could have broad applications in treating inflammatory conditions, including cardiovascular disease. BioAge's positive early-stage results with BGE-102 suggest the compound could become an important new therapeutic option if it continues to demonstrate efficacy and safety in further clinical testing.
The details
In the Phase 1 trial, BioAge's BGE-102 showed a robust 86% reduction in hsCRP levels, a key biomarker of inflammation associated with cardiovascular disease risk. The drug also exhibited a favorable safety profile, with no serious adverse events reported. These results position BGE-102 for potential proof-of-concept trials in cardiovascular indications later this year, as the company looks to advance the program.
- BioAge Labs completed its IPO in October 2024, raising $238 million.
- The positive Phase 1 results for BGE-102 were reported in April 2026.
The players
BioAge Labs
A biotech company based in Emeryville, California that is developing novel therapies targeting the biology of aging, including an oral NLRP3 inhibitor drug candidate called BGE-102.
BGE-102
BioAge Labs' lead drug candidate, an oral NLRP3 inhibitor that demonstrated an 86% reduction in high-sensitivity C-reactive protein (hsCRP) levels and a favorable safety profile in a Phase 1 clinical trial.
What’s next
BioAge plans to initiate proof-of-concept trials for BGE-102 in cardiovascular disease indications later in 2026 to further evaluate the drug's potential.
The takeaway
BioAge's early success with its oral NLRP3 inhibitor BGE-102 highlights the promise of this emerging drug class for treating inflammatory conditions like cardiovascular disease. If the compound continues to demonstrate strong efficacy and safety in future trials, it could become an important new therapeutic option for patients at risk of heart disease.
